Clinical research
Vertos Medical is committed to building the science behind its mild* procedure. Working with a scientific advisory board composed of clinical experts in pain medicine and neurosurgery, the company has developed a comprehensive clinical program to validate the safety and efficacy of the mild devices and procedure. This program includes several post-market clinical studies at leading pain centers across the country.
mild Post-Market Clinical Studies
Completed
- mild Acute Safety Study: 90-patient, multi-center, retrospective study, with results published in Pain Physician Journal
See press release on study findings
See Pain Physician Journal article
Ongoing
- MiDAS I (mild® Decompression Alternative to open Surgery): 75-patient, open-label, single-arm, prospective, multi-center, IRB-approved study; enrollment completed
See press release on six-week study findings
See press release on twelve-week study findings
- MiDAS II: 50-patient, open label, single-arm, multi-center, prospective IRB-approved study; now enrolling
- ESI-I Trial: 40-patient, single-site, randomized, double-blind, prospective, IRB-approved study comparing mild and epidural steroid injections; now enrolling
- ESI-II Trial: 40-patient, multi-site, randomized, double-blind, prospective, IRB-approved study comparing mild and epidural steroid injections; now enrolling
- Prospective-50 Trial: 50-patient, single-site, open label, single-arm, prospective, IRB-approved study; now enrolling
- High Risk Trial: 14-patient, single-site, open label, single-arm, prospective, IRB-approved study on high-risk patients; enrollment completed
Fully detailed study methodologies, are available upon request.
* Vertos mild is FDA cleared for treating central canal stenosis of the lumbar spine.
